# Microbiome Therapeutics Design Agent

**ID:** `biomedical.microbiome.therapeutics`
**Version:** 1.0.0
**Status:** Experimental
**Category:** Microbiome / Therapeutics

---

## Overview

The **Microbiome Therapeutics Design Agent** designs synthetic microbial consortia and engineered probiotics for treating diseases through microbiome modulation. AI is transforming this field by enabling the design of synthetic microbial communities tailored to treat conditions such as IBD, IBS, metabolic disorders, and even neurological conditions through the gut-brain axis.

This agent integrates microbiome data analysis, metabolic modeling of microbial communities, and machine learning to design rationally composed therapeutic consortia.

---

## Key Capabilities

### 1. Therapeutic Modalities

| Type | Description | Applications |
|------|-------------|--------------|
| **Live Biotherapeutics** | Defined microbial consortia | IBD, C. diff |
| **Engineered Probiotics** | Genetically modified strains | Drug delivery |
| **Fecal Microbiota Transplant** | Full community transfer | Recurrent CDI |
| **Postbiotics** | Microbial metabolites | Immune modulation |

### 2. Disease-Microbiome Associations

| Disease | Microbiome Signature | Therapeutic Target |
|---------|---------------------|-------------------|
| **IBD** | ↓Faecalibacterium, ↓diversity | Restore butyrate producers |
| **C. difficile** | Dysbiosis, ↓diversity | Colonization resistance |
| **Obesity** | ↑Firmicutes/Bacteroidetes | Metabolic rebalancing |
| **Depression** | ↓SCFA producers | Gut-brain axis modulation |
| **IBS** | Variable dysbiosis | Symptom-guided design |

### 3. Consortium Design

- **Species selection:** Function-based curation
- **Metabolic complementarity:** Cross-feeding optimization
- **Colonization modeling:** Persistence prediction
- **Safety assessment:** Pathogenicity screening

### 4. AI/ML Applications

- **Microbiome signature identification:** Disease biomarkers
- **Response prediction:** Patient stratification
- **Consortium optimization:** Genetic algorithm design
- **Metabolite prediction:** Community metabolic output

---

## Usage

### Example Prompt

```text
Design a defined microbial consortium for treating ulcerative colitis.

Requirements:
- Increase butyrate production
- Restore gut barrier function
- Anti-inflammatory activity
- 5-10 species maximum
- Generally Regarded as Safe (GRAS) strains preferred
```

### Expected Output

```
## Therapeutic Consortium Design: Ulcerative Colitis

### Disease Analysis

#### UC Microbiome Signature
| Change | Taxa | Functional Impact |
|--------|------|-------------------|
| ↓ Depleted | Faecalibacterium prausnitzii | ↓ Butyrate |
| ↓ Depleted | Roseburia intestinalis | ↓ Butyrate |
| ↓ Depleted | Akkermansia muciniphila | ↓ Barrier function |
| ↑ Increased | Escherichia/Shigella | ↑ Inflammation |
| ↑ Increased | Fusobacterium | ↑ Inflammation |

#### Therapeutic Targets
1. **Butyrate production:** Anti-inflammatory, barrier maintenance
2. **Mucin production:** Barrier function
3. **Pathogen exclusion:** Competitive inhibition
4. **Immune modulation:** Regulatory T-cell induction

### Designed Consortium: UC-Restore-8

| Species | Function | Safety | Selection Rationale |
|---------|----------|--------|---------------------|
| **Faecalibacterium prausnitzii A2-165** | Butyrate producer, anti-inflammatory | GRAS | Major butyrate producer, depleted in UC |
| **Roseburia intestinalis L1-82** | Butyrate producer | GRAS | Cross-feeds with F. prausnitzii |
| **Akkermansia muciniphila MucT** | Mucin degrader, barrier support | GRAS | Enhances gut barrier |
| **Bifidobacterium longum BB536** | Acetate producer, immune modulation | GRAS, Probiotic | Cross-feeds butyrate producers |
| **Lactobacillus rhamnosus GG** | Competitive exclusion, IL-10 induction | GRAS, Probiotic | Pathogen exclusion |
| **Bacteroides thetaiotaomicron VPI-5482** | Fiber degradation, cross-feeding | GRAS | Provides substrates |
| **Propionibacterium freudenreichii ITG P20** | Propionate producer | GRAS | Anti-inflammatory |
| **Blautia obeum DSM 25238** | Butyrate producer | GRAS | Bile acid metabolism |

### Metabolic Modeling

#### Cross-Feeding Network
```
Dietary Fiber
    ↓ B. thetaiotaomicron
Simple sugars + Acetate
    ↓ Bifidobacterium
Acetate + Lactate
    ↓ F. prausnitzii + Roseburia
    ↓
BUTYRATE → Colonocyte energy, anti-inflammatory
```

#### Predicted Metabolic Output
| Metabolite | Predicted Conc. (mM) | Reference (Healthy) |
|------------|----------------------|---------------------|
| Butyrate | 18-24 | 15-25 |
| Acetate | 45-55 | 40-60 |
| Propionate | 12-16 | 10-20 |
| Lactate | 2-4 | 1-5 |

### Safety Assessment

| Species | Pathogenicity | ABR Genes | Virulence | Risk |
|---------|---------------|-----------|-----------|------|
| F. prausnitzii | None known | 0 | None | Very Low |
| R. intestinalis | None known | 0 | None | Very Low |
| A. muciniphila | None known | 0 | None | Low |
| B. longum | None known | 0 | None | Very Low |
| L. rhamnosus | Rare opportunistic | 0 | None | Very Low |
| B. thetaiotaomicron | None known | 0 | Low invasin | Low |
| P. freudenreichii | None known | 0 | None | Very Low |
| B. obeum | None known | 0 | None | Very Low |

### Formulation Recommendations

| Parameter | Specification |
|-----------|--------------|
| **Total CFU** | 10¹⁰ - 10¹¹ per dose |
| **Formulation** | Enteric-coated capsule |
| **Storage** | -80°C (frozen) or lyophilized |
| **Dosing** | Once daily with food |
| **Duration** | 8-12 weeks initial course |

#### Species Ratios
```
F. prausnitzii      : 25%
Roseburia           : 20%
Akkermansia         : 15%
Bifidobacterium     : 15%
Lactobacillus       : 10%
Bacteroides         : 5%
Propionibacterium   : 5%
Blautia             : 5%
```

### Predicted Clinical Outcomes

| Endpoint | Prediction | Confidence |
|----------|------------|------------|
| Clinical remission (8 weeks) | 45-55% | Medium |
| Endoscopic improvement | 35-45% | Medium |
| Fecal calprotectin ↓ | 40-50% reduction | Medium |
| Butyrate levels ↑ | 2-3x increase | High |

### Personalization Strategy

| Patient Subgroup | Modification |
|------------------|--------------|
| Severe dysbiosis | Add pre-treatment antibiotic |
| High inflammation | Add more F. prausnitzii |
| Low diversity | Add additional Bacteroides |
| Previous FMT failure | Include phage targeting E. coli |
```

### LLM Agent Integration

```python
@tool
def design_microbial_consortium(
    disease: str,
    therapeutic_goal: list[str],
    max_species: int = 10,
    safety_requirement: str = "GRAS"
) -> str:
    """
    Designs therapeutic microbial consortium for disease treatment.

    Args:
        disease: Target disease
        therapeutic_goal: List of goals (butyrate, barrier, inflammation)
        max_species: Maximum number of species
        safety_requirement: GRAS, probiotic, or experimental

    Returns:
        Consortium design with rationale and predictions
    """
    pass
```

---

## Prerequisites

### Required Tools/Databases

| Resource | Purpose | Access |
|----------|---------|--------|
| **GMrepo** | Gut microbiome database | Public |
| **AGORA** | Microbiome GEMs | Public |
| **BacDive** | Bacterial metadata | Public |
| **PATRIC** | Pathogen database | Public |

### Dependencies

```
cobra>=0.26
micom>=0.32
pandas>=1.5
scikit-learn>=1.3
```

---

## References

- **Buffie et al. (2015):** "Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile." *Nature*
- **Suez et al. (2018):** "Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics." *Cell*

---

## Author

**MD BABU MIA**
*Artificial Intelligence Group*
*Icahn School of Medicine at Mount Sinai*
md.babu.mia@mssm.edu
